NEW YORK (GenomeWeb) – Molecular diagnostics firm Transgenomic announced today that it has signed a non-exclusive North American distribution agreement with VWR for its ICEme mutation enrichment kits.
Specific terms of the deal were not disclosed.
The customizable kits, which were launched last year, are based on Transgenomic's multiplexed ICE-COLD PCR (MX-ICP) technology and are designed to provide accurate detection of genetic mutations in any type of sample and using any downstream sequencing platform.
"We view this distribution agreement with VWR as a significant milestone in the commercialization of our MX-ICP technology," Transgenomic President and CEO Paul Kinnon said in a statement. "Feedback from our early customers confirms the ability of our ICEme kits to make it possible for any research lab with sequencing capability to conduct genomics-based cancer research."
Last summer, Transgenomic inked deals to distribute the kits in China and Japan through Spectron Scientific and Sowa Trading Company, respectively.